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Abstract
New generation in-vitro high throughput screening (HTS) assays for the assessment of engineered nanomaterials provide an opportunity to learn how these particles interact at the
cellular level, particularly in relation to injury pathways. These types of assays are often
characterized by small sample sizes, high measurement error and high dimensionality as multiple cytotoxicity outcomes are measured across an array of doses and durations of exposure.
In this article we propose a probability model for toxicity profiling of engineered nanomaterials. A hierarchical framework is used to account for the multivariate nature of the data by
modeling dependence between outcomes and thereby combining information across cytotoxicity pathways. In this framework we are able to provide a flexible surface-response model
that provides inference and generalizations of various classical risk assessment parameters.
We discuss applications of this model to data on eight nanoparticles evaluated in relation to
four cytotoxicity parameters.

Keywords: Additive Models, Dose Response Models, Hierarchical Models, Multivariate, Nanotoxicology.
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1 INTRODUCTION
Nanotechnology is rapidly growing and currently used in various industries such as food,
agriculture, electronics, textiles and health care. The widespread use of engineered nanomaterials (ENM) in over 800 consumer products increases the likelihood that these materials
will come into contact with humans and the environment (Maynard et al. 2006, Kahru and
Dubourguier 2009). Many biological processes take place at the nanoscale level, and the
introduction of ENMs into living organisms could lead to interference in the molecular and
cellular processes that are critical to life (Nel et al. 2009). This potential for human and environmental hazard has spurred recent interest in early identification of potentially hazardous
nanomaterials. Knowledge about the potential hazard of nanomaterials is still lacking and a
lot of study is required to understand how ENM properties such as size, shape, agglomeration state, solubility, and surface properties could lead to hazard generation at the nano-bio
interface (Stern and McNeil 2008, Nel et al. 2006).
Current research in nano-toxicology includes new generation high throughput screening
(HTS) assays, which enable the simultaneous observation of multiple cellular injury pathways
across an array of doses and times of exposure. These assays provide an opportunity to help
define biological relationships and may suggest which nanoparticles are likely to have an in
vivo effect. While HTS assays cannot replace traditional animal studies, they are less costly,
less labor intensive, and can be used to explore the large number of potential nanomaterial
variables that can influence human health hazard (Meng et al. 2010, Stanley et al. 2008,
Maynard et al. 2006). The feasibility and utility of HTS assays have been illustrated in various fields such as functional genomics, with the use of microarray technology, as well as in
pharmacology for the rapid screening of potential drug targets (Hoheisel 2006, White 2000).
In toxicology, risk assessment involves the characterization of hazard as well as the potential
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for exposure while accounting for all assumptions and uncertainties. The HTS framework
provides a wealth of information about cellular injury pathways but proves a challenge for
the classic risk assessment paradigm. In fact, there is still disagreement, in the HTS setting,
on how to define and how appropriate are classical risk assessment parameters such as no
observable adverse effect level (NOAEL), the lowest observable adverse effect level (LOAEL),
and the dose that produces 50% of the maximum response (EC50), among others.
In this article, for example, we analyze data on eight metal and metal oxide nanoparticles, monitored in relation to four cellular injury responses, derived from the hierarchical
oxidative stress model of Nel et al. (2006) and Xia et al. (2006). All four outcomes are measured contemporaneously over a grid of ten doses and seven hours of exposure (see Figures
4 and ??). The four responses measured include mitochondrial superoxide formation, loss
of mitochondrial membrane potential, elevated intracellular calcium, and membrane damage
(George et al. 2010). For increasing dosage and duration of exposure, we observe typical dose
response kinetics, with response values possibly depending on one another. The modeling
challenge lies in the definition of a flexible and interpretable probabilistic representation for
a family of dependent dose-response random surfaces.
Parametric functions such as the families of sigmoidal curves are frequently used to fit
dose response data. Some commonly used sigmoidal models include log-logistic models, lognormal models, and Weibull models (see Ritz 2010 for a recent review of these models).
The log-logistic functions are the most frequently used for modeling dose-response data in
toxicology. The four parameter log-logistic model can be expressed as follows
f (x; b, c, d, h) = c +

d−c
.
1 + exp[b{log(x) − log(h)}]

(1)

Here the parameter h, the inflection point in the curve, provides a convenient risk assessment parameter since it can be interpreted as the 50% effective or inhibitory dose (EC50,
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IC50) (Emmens 1940). Other special cases of this model include the 3 parameter log-logistic
model which leads to the famous Hill equation (Hill 1910) and special cases of the MichaelisMenton kinetics. Further extensions of these models include the five parameter log-logistic
function which provides a bit more flexibility by allowing the function to be asymmetric
(Finney 1979) and the Brain-Cousens model, which includes an extra parameter to account
for a possible favorable response to a toxin at low concentrations (Calabrese and Baldwin
2003). In general these models assume that the dose-response function is completely known
apart from the few parameters to be estimated, usually by determining which values of the
parameters result in the best fit to the dose-response function.
Several other methods have been proposed to model nonlinear dose-response relationships
relaxing strictly parametric assumptions. Ramsay (1988) proposed the use of monotone regression splines to model a dose-response function. In this case, piecewise polynomials or
splines can allow greater flexibility in modeling the dose-response curve while achieving
monotonicity by imposing constraints on the estimated function. Li and Hunt (2004) proposed the use of linear B-splines with one random interior knot to model a nonlinear dose
response curve. In this context, the random interior knot provides inference on the dose
at which the toxin begins to takes effect and thereby provides a useful parameter for risk
assessment. Kong and Eubank (2006) suggested the use of smooth functions that combine
smoothing spline techniques and the non-negativity properties of cubic B-splines to estimate
the dose response curve. The use of non-parametric techniques to estimate dose response
curves often provides a more realistic representation of the data generating process. At the
same time, however, some of these techniques make it more difficult to interpret the model
in terms of classical risk assessment.
Recent literature advocates the simultaneous use of multiple outcomes to assess risk.
Regan and Catalano (1999) proposed a bivariate dose-response model that accounts for
5

the dependence between outcomes of developmental toxicity using generalized estimating
equations. Geys et al. (2001) proposed a similar model for risk assessment of developmental
toxicity, but approach the problem using latent variables. Yu and Catalano (2005) suggested
a model for quantitative risk assessment of bivariate continuous measures of neurotoxicity
using percentile regression. These methods are often aimed at the analysis of one potentially
toxic agent as it relates to adverse event or continuous outcomes observed in association
with exposure over a range of doses. Their direct applicability to the general HTS setting
described earlier is therefore limited.
Here, we propose a hierarchical dose-response model for the analysis of HTS data in nanotoxicology. Our model builds on earlier work (Hastie and Tibshirani 1986, Li and Hunt
2004), expanding on them to account for the multivariate nature of the data and to address
the estimation of a series of two dimensional dose-response surfaces. We provide a flexible
framework for modeling dose and duration response kinetics jointly, while providing inference on several risk assessment parameters of interest. We utilize a hierarchical structure to
define dependence between outcomes and thereby borrow strength across injury pathways,
providing the basis for a comprehensive risk assessment paradigm in HTS studies. We account for outlying observations via a T-distributed error model and describe how to carry
out inference for the model parameters and their functions on the basis of simulated draws
from their posterior distribution. To our knowledge we are the first to propose a principled
Statistical methodology for the joint analysis of this new generation of in-vitro data.
The remainder of the article is organized as follows. In Section 2 we introduce the proposed
model. In Section 3 we discuss parameter estimation and associated inferential details.
Section 4 employs the proposed model for the analysis of 8 metal oxide nanomaterials and
describes inference for various risk assessment parameters of interest. We conclude with a
critical discussion of the limitations and possible extensions of our method in Section 5.
6

2 MODEL FORMULATION
2.1 Model Description
In this section we describe a dose-response model for a general HTS study, where we monitor a multivariate continuous outcome y, corresponding to J cytotoxicity parameters, in
association with the exposure of a number of cells to I different ENMs. More precisely, let
yijk (d, t) denote a multivariate response corresponding to ENM i (i = 1, ..., I), cytotoxicity
parameter j (j = 1, ..., J), and replicate k (k = 1, ..., K) at dose d ∈ [0, D] and time t ∈ [0, T ].
Clearly, in typical applications one observes y over a discrete set of doses d˜ = (d1 , ..., dm1 )0
and exposure times t̃ = (t1 , ...., tm2 )0 . However, for clarity of exposition, we simplify our
notation without loss of generality and refer to a general dose d ∈ [0, D] and time t ∈ [0, T ].
We introduce the following 4-stage hierarchical model.
Stage 1: Sampling Model
The observed response of particle i, cytotoxicity parameter j and replicate k is modeled as:
yijk (d, t) = mij (d, t) + ijk (d, t),

(2)

where ijk (d, t) ∼ N (0, σ2j /τi ). Here mij (d, t) denotes the response surface for particle i and
outcome j. This quantity describes dose and duration kinetics for all d ∈ [0, D] and t ∈
[0, T ] and is expected to exhibit a non-linear dynamic over these domains. The distribution
of yijk is modeled in terms of the error term ijk as a scaled mixture of normal random
variables to account for outlying observations. The error variance is defined in terms of the
measurement error variance σ2j , specific to cytotoxicity parameter j, and on ENM-specific
variance inflation parameter τi . If we define the joint distribution of ijk (d, t) and τi as
P (ijk (d, t), τi ) = P (ijk (d, t) | τi , σj )P (τi | ν), choosing ijk (d, t) | τi , σj ∼ N (0, σ2j /τi ) and
τi | ν ∼ Gamma(ν/2, ν/2), it can be shown that the marginal density of ijk (d, t) | σ2j is
7

distributed as a T (σ2j , ν) (West 1984). Under this framework, we can borrow strength across
all ENM by assuming the error variance is the same, but retain robustness in the model by
allowing ENM specific departures from normality. We allow the measurement error σj to
vary between cytotoxicity parameters due to heterogeneity in the cytotoxicity outcomes.
Stage 2: Response model at the ENM by cytotoxicity parameter level
The dose-response surface mij (d, t) spans two dimensions (dose and time) and is modeled in
an additive fashion as described by Hastie and Tibshirani (1986). Let {αij , β 0ij , φ0ij , γ 0ij , ψ 0ij , δ 0ij , χ0ij )0
be a parameter vector indexing the dose response surface mij (d, t). We define
mij (d, t) = αij + fij (d; φij , β ij ) + gij (t; ψ ij , γ ij ) + hij (d, t; χij , δ ij ).

(3)

Here fij (d; φij , β ij ) is a function modeling the effect of dose d on response j for ENM i,
Similarly, gij (t; ψ ij , γ ij ) is the function modeling the effect of time t and hij (d, t; χij , δij ) is
the function modeling the interactive effect of dose and time. More specifically, we model the
interaction of dose and time in a semi-parametric fashion as hij (dt; χij , δ ij ). This parameterization allows us to retain direct interpretation of the model parameters, while avoiding
over-fitting of sparse data. To insure Likelihood identifiability we require, without loss of
generality, that fij (d = 0; φij , β ij ) = 0, gij (t = 0; ψ ij , γ ij ) = 0, and hij (dt = 0; χij , δ ij ) = 0.
The parameters αij can therefore be interpreted as the background response level for each
particle and outcome.
We model dose response curves fij (d; φij , β ij ), duration response curves gij (t; ψ ij , γ ij ),
and dose-time response curves hij (dt; χij , δ ij ) as a linear combination of basis functions.
Specifically, we use linear B-splines with two random interior knots as points where the
slope changes in a piecewise linear fashion. Let B(x, η) denote a 4-dimensional B-spline
basis with interior knots η = (η1 , η2 )0 . Also, let β ij = (βij1 , .., βij4 )0 , γ ij = (γij1 , ..., γij4 )0 ,
and δ ij = (δij1 , ..., δij4 )0 be two 4-dimensional vectors of spline coefficients. The functions
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fij (d; φij , β ij ), gij (t; ψ ij , γ ij ), and hij (dt; χij , δ ij ) can then be represented as follows:
fij (d; φij , β ij ) = B(d, φij )0 β ij ,
gij (t; ψ ij , γ ij )

=

B(t, ψ ij )0 γ ij ,

(4)

hij (dt; χij , δ ij ) = B(dt, χij )0 δ ij .
Identifiability restrictions, fij (d = 0; φij , β ij ) = 0, gij (t = 0; ψ ij , γ ij ) = 0, and hij (dt =
0; χij , δ ij ) = 0 are implemented by fixing βij1 = 0, γij1 = 0 and δij1 = 0, for all particles
and outcomes (see Figure 2 for an illustration).
Modeling dose and duration response curves as piecewise linear functions allows for good
flexibility while maintaining direct interpretability of the model parameters. We recall that,
in our formulation the interior knots are estimated as random quantities. This allows,
marginally, for a smooth dose-response trajectory that is automatically adjusted to fit the
data. The main advantage of the proposed functional representation is that, in the absence
of a dose-time interaction, one can interpret the first interior knot φij1 as the dose at which
ENM i becomes toxic in relation to cytotoxicity parameter j (Maximal Safe Dose - similar to
the classical NOAEL concept). A similar interpretation can be given to ψij1 , in relation to
duration response. Note, that the foregoing interpretation is contingent on fixing βij2 = 0,
γij2 = 0, and χij2 = 0 when assuming no effect before the first change-point, and βij2 ≤ 0,
γij2 ≤ 0, and χij2 ≤ 0 when assuming a tonic effect before the first change-point. In the
presence on a dose-time interaction, interpretation changes slightly and we instead consider
the idea of safe exposure regions, which represent doses and time exposure combinations
which do not induce cytotoxicity (see figure 5 for details). Finally, in the absence of an
interaction, the parameters φij2 and ψij2 are respectively interpreted as the dose and time
at which the response stabilizes or cells start a possible recovery process.
We can expand the model further, to allow for the exclusion of interaction functions, where
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not needed. To do that we include a latent indicator variable ρij , so that for each particle i
and outcome j

 αij + fij (d; φ , β ) + gij (t; ψ , γ )
ij
ij
ij
ij
mij (d, t) =
 α + f (d; φ , β ) + g (t; ψ , γ ) + h (dt; χ , δ )
ij
ij
ij
ij
ij
ij
ij
ij
ij
ij

if ρij = 0
if ρij = 1,
(5)

where ρij ∼ Bern(π) and π ∼ U (0, 1). We require that, if ρij = 0, hij (dt; χij , δ ij ) > 0, to
ensure identifiability. The indicator variable ρij , can then be used to test explicitly for the
dose-time interactions. The exchangeable Bernoulli trials prior on ρij is designed to account
for multiplicities (Scott and Berger 2006). This trans-dimensional parameterization is key to
avoid overfitting, facilitate parameter interpretation and allow for testing of specific scientific
hypotheses related to the biological interference of nanomaterials.
For each ENM i and response j, we define the following prior distributions for αij , β ij , γ ij ,
and δ ij :
αij

∼ N (αoi , σα2 i ),

βij

∼ N4 (βoi , Σβi )I{βij1 = 0; βij2 ≤ 0; (βij3 , βij4 ) ≥ 0},

γij

∼ N4 (γoi , Σγi )I{γij1 = 0; γij2 ≤ 0; (γij3 , γij4 ) ≥ 0},

(6)

δij | ρij = 1 ∼ N4 (mδij , vδij )I{δij1 = 0; δij2 ≤ 0; (δij3 , δij4 ) > 0}.
The truncated support for βij , γij , and δij imposes functional constraints on f (·), g(·), and
h(·), which are consistent with the expected behavior of canonical dose and duration kinetics.
At the same time, however, it allows for the system to recover by permitting a decreasing
slope after the second change-point. The covariance matrix Σβi has diagonal elements σβi` ,
` = 1, .., 4, and off diagonal elements equal to 0. Similarly for Σγi .
Prior distributions for φij , ψ ij , and χij are defined to satisfy the following constraints:
(0 < φij1 < φij2 < D), (0 < ψij1 < ψij2 < T ), and (0 < χij1 < χij2 < DT ). More precisely,
we assume that the joint distribution of the interior dose and duration knots follows a
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generalized bivariate Beta density function, so that
φij ∼ B2 (aφ1 , bφ1 , aφ2 , bφ2 , D),
ψij ∼ B2 (aψ1 , bψ1 , aψ2 , bψ2 , T ),

(7)

χij ∼ B2 (aχ1 , bχ1 , aχ2 , bχ2 , DT ).
Here we assume that a random vector x = (x1 , x2 )0 is distributed according to a generalized bivariate Beta distribution function (x ∼ B2 (a1 , b1 , a2 , b2 , m)), with support S(x) =
{(x1 , x2 ) : 0 < x1 < x2 < m}, if and only if:
p(x | a1 , b1 , a2 , b2 , m) = p(x1 | a1 , b1 , m) p(x2 | x1 , a2 , b2 , m)
=

1
xa11 −1 (m − x1 )b1 −1
1
(x2 − x1 )a2 −1 (m − x2 )b2 −1
.
B(a1 , b1 )
ma1 +b1 −1
B(a2 , b2 )
(m − x1 )a2 +b2 −1
(8)

The foregoing formulation, can be seen as a generalization of the Dirichlet distribution over
a two-dimensional simplex. This general formulation can be simplified further, in order to
achieve a right-skewed marginal distribution for x1 and a uniform conditional distribution
for x2 given x1 . This is achieved by assuming b1 > a1 > 1 and a2 = b2 = 1.
Making use of this construction, we simplify the prior in (7) as follows
φij ∼ B2 (1, λφi1 , λφi2 , 1, 1, D)I{λφi2 > λφi1 > 1},
ψij ∼ B2 (1, λψi1 , λψi2 , 1, 1, T )I{λψi2 > λψi1 > 1},

(9)

χij ∼ B2 (1, lχi1 , lχi2 , 1, 1, T )I{lχi2 > lχi1 > 1}.
This formulation favors (a-priori) the choice of conservative values for the location of the
first change-point and a relatively diffuse prior for our second change-point (see Figure 2).
Stage 3: Response model at the ENM level
For each ENM i, we exploit conditional conjugacy to define the following prior distributions
for population level parameters:
αoi ∼ N (mαi , vαi ),

βoi ∼ N4 (mβi , vβi ),
11

γoi ∼ N4 (mγi , vγi ).

(10)

In the absence of an interaction, the parameters βoi and γoi represent summaries of the dose
and duration response trajectories across all outcomes, and the αoi parameters represent a
summary of the baseline response across all outcomes. In the presence of an interaction, we
may construct these summaries, conditionally on specific doses and durations of exposure.
Finally, considering the prior distribution introduced in (9) we define a prior model for
population level parameters λφi = (λφi1 , λφi2 ) and λψi = (λψi1 , λψi2 ) as follows:
λφi` ∼ Gamma(aλφi` , bλφi` ),

λψi` ∼ Gamma(aλψi` , bλψi` )

(11)

where, ` = 1, 2. The parameters λφi and λψi can be used to construct summaries of dose and
duration response change-points across all outcomes. Shape hyperparameters (aλφi` , bλφi` )
and (aλψi` , bλψi` ) can be tuned to favor more or less conservative values for the change-point
locations at the particle level.
Stage 4: Hyperpriors
We complete the model by specifying prior distributions on our hyperparameters as follows:
1/σ2j ∼ Gamma(aj , bj ),

1/σα2 i ∼ Gamma(aαi , bαi ),

1/σβ2i ∼ Gamma(aβi , bβi ),

1/σγ2i

(12)

∼ Gamma(aγi , bγi ).

We model our precision parameters as gamma distributions, exploiting conditional conjugacy. Again, prior parameters can be tuned to define more or less informative distributions
consistently with the scale of the outcomes (Gelman 2006). Note, that in our formulation,
x ∼ Gamma(a, b) denotes a Gamma distributed random quantity with shape a and rate b,
such that E(x) = a/b.
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3 Estimation and Inference
3.1 Posterior Simulation via MCMC
Using the B-spline representation introduced in Section 2.1, we can write the expected j-th
response level associated with ENM i, at dose d, and exposure time t as

 αij + B(d, φ )0 β + B(t, ψ )0 γ
ij
ij
ij
ij
mij (d, t; αij , β ij , · · ·) =
 α + B(d, φ )0 β + B(t, ψ )0 γ + B(dt, χ )0 δ
ij
ij
ij
ij
ij
ij
ij

if ρij = 0
if ρij = 1

Let β = {β ij : i = 1, . . . , I, j = 1, . . . , J}, γ = {γ ij : i = 1, . . . , I, j = 1, . . . , J},
and δ = {δ ij : i = 1, . . . , I, j = 1, . . . , J} denote the full set of spline coefficients. Furthermore, consider knot parameters φ = {φij : i = 1, . . . , I, j = 1, . . . , J}, ψ = {ψ ij :
i = 1, . . . , I, j = 1, . . . , J}, χ = {χij : i = 1, . . . , I, j = 1, . . . , J} and background response
parameters α = {αij : i = 1, . . . , I, j = 1, . . . , J}. Finally, let σ2 = (σ21 , . . . , σ2J )0 and
τ = (τ1 , . . . , τI )0 . If we denote with Y the complete set of response values for all particles
and cytotoxicity outcomes, the likelihood function can be written as follows:
(
"
)#
2
Y
(
y
(d,
t)
−
m
(d,
t;
·
·
·)
)
ijk
ij
;
L(β, γ, δ, φ, ψ, χ, α, σ2 , τ , ρ | Y) ∝
(σ2j /τi )−1/2 exp −
2σ2j /τi
i,j,k,d,t
(13)
where the product is taken over all replicates k, particles i, outcomes j, doses d and times t.
We are interested in the posterior distribution
P (β, γ, δ, φ, ψ, χ, α, σ2 , τ , ρ | Y) ∝ L(β, γ, δ, φ, ψ, χ, α, σ2 , τ , ρ | Y) P (β, γ, δ, φ, ψ, χ, α, σ2 , τ , ρ),
(14)
where the prior model, P (β, γ, δ, φ, ψ, χ, α, σ2 , τ , ρ), is fully described in Section 2.1. This
quantity is, however, unavailable in closed analytic form, therefore we base our inference on
Markov Chain Monte Carlo (M CM C) simulations.
13

The proposed posterior simulation algorithm combines Gibbs steps within MetropolisHastings steps in a hybrid sampler, where we update parameters component-wise (Tierney
1994). We directly sample components when closed-form full conditional distributions are
available using a Gibbs sampling algorithm (Geman and Geman 1984, Gelfand and Smith
1990); otherwise, we use the Metropolis-Hastings (MH) approach (Metropolis et al., 1953).
Available full conditional distributions are given in supplementary Appendix A. As we are
considering selection of interaction functions in a trans-dimensional setting, we implement
a reversible jumps algorithm to jump between models with and without the dose-time interaction function hij (dt; χij , δ ij ) (Green 1995). The model indicator ρij and corresponding
model parameters δ ij and χij are updated jointly using reversible jump MCMC steps. After the model structure has been specified, the model parameters are updated from their
corresponding conditional posterior distributions. The proposed sampling scheme can be
summarized as follows.
1. Fixed dimensional updates. Given the current state of the latent interaction indicators
ρij , response surfaces are uniquely defined as in (5). Posterior sampling is here standard
and proceeds by updating spline coefficients β, γ and δ from their conditional posterior via
direct simulation (Gibbs step - Appendix A). Knots parameters φ, ψ and χ are updated via
a MH step. For example, when sampling parameters φ we use an appropriate proposal kernel
q(φ0ij` , φ1ij` ) to efficiently construct Markov chains with the desired stationary distribution.
While accounting for the fact that φij1 < φij2 , we consider uniform proposal densities of the
form
q(φ1ij` | φ0ij` )=U (φ0ij` − wφij` , φ0ij` + wφij` )I(Sφ ),

(15)

where, ` = 1, 2. Here Sφ denotes the appropriate support and must satisfy the constraints
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(0 < φij1 < φij2 < D). Proposed values of φij` are accepted with the following probabilities:
(

p(φ1ij` | yijk , θ\φ ) q(φ0ij` | φ1ij` )
min 1;
p(φ0ij` | yijk , θ\φ ) q(φ1ij` | φ0ij` )

)
, ` = 1, 2.

(16)

To tune proposal kernels, each φij` was sampled using an initial value of w which was recalibrated throughout the burn-in period to achieve an acceptance rate between 30% and
70% (Roberts and Rosenthal 2001). Specifically, the acceptance rate of φij` was monitored
every 200 iterations throughout the burn-in period with wφij` adjusted appropriately if the
acceptance rate did not fall within the desired range. A similar Metropolis-Hastings scheme
was adapted for sampling the duration parameters ψ, dose-time interaction parameters χij |
ρij = 1, as well as for population level knot parameters.
2. Trans-dimensional updates. We sample the model space by randomly proposing the birth
or death of dose-time interaction functions hij (·). This is accomplished by selecting a particle
i and outcome j at random and by jointly updating ρij , δ ij and χij . In detail:
1. For uniformly random i ∈ (1, ...I) and j ∈ (1, ...J), propose a systematic change
ρ0ij → ρ1ij = 1 − ρ0ij . We assume for the moment that we propose moving from ρ0ij = 0
to ρ1ij = 1, implying the birth of a new interaction function hij (·).
2. Propose new knots and spline coefficients δ 1ij ∼ q(δ 1ij ) and χ1ij ∼ q(χ1ij ).
3. Accept the proposed move with probability τb = min(1, Rb ), where
Rb =

p(yijk | δ 1ij , χ1ij , ρ1ij , θ\δij ,χij ,ρij ) p(δ 1ij | ρ1ij )p(χ1ij | ρ1ij ) p(ρ1ij )
,
p(yijk | ρ0ij , θ\δij ,χij ,ρij )
p(ρ0ij )
q(δ 1ij )q(χ1ij )

(17)

where we use θ\ω to denote all model parameters, with the exception of ω.
In the case where the proposed move would imply a death of an interaction function (ρ0ij =
1 → ρ1ij = 0), the acceptance probabilty would simply be τd = 1/τb .
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While the proposal densities q(δ ij ) q(χij ) in 2. can in theory be defined almost arbitrarily,
to guarantee efficient exploration of the model space we consider truncated multivariate normal proposals for δ ij and χij centered around regions of high posterior probability. Efficient
optimization within the MCMC iterations is achieved using standard profile likelihood ideas
(Severini and Stainwalis 1994).

3.2 Posterior Inference
In this section we discuss inference on ENM specific risk assessment parameters, based on
draws from the posterior distribution described in Section 3.1. Table 1 summarizes several
quantities of interest such as the maximal safe dose, maximal safe exposure time, and the
maximal response. This list is not exhaustive. However, other risk assessment parameters of
interest, like benchmark doses (BMD) or effective concentrations (ECα) are easily obtained
from our model output in a numerical fashion. Again, in the case of a dose-time interaction,
these quantities are defined conditionally on specific doses and durations of exposure.
(n)

(n)

(n)

(n)

(n)

(n)

(n)

(n)

Let φij , ψij , χij , βij , γij , δij , αij and ρij , n = 1, ..., N , denote N MCMC draws
from the posterior distribution of φij , ψij , χij , βij , γij , αij and ρij . In the absence of an
(n)

(n)

interaction term, posterior samples φij1 and ψij1 directly provide us with an approximation
of the posterior distribution for the maximal safe dose, and maximal safe exposure time.
∗(n)

(n)

(n)

We can also obtain the posterior samples for the overall dose effect, βij3 = βij3 /(φij2 −
(n)

φij1 ), which is the slope of the dose-response curve between φij1 and φij2 . Similarly, we
can obtain the posterior distribution for the overall time effect, using posterior samples
∗(n)

(n)

(n)

(n)

γij3 = γij3 /(ψij2 − ψij1 ). In the presence of a dose-time interaction, we can define any
of the summaries described above conditionally on a given dose and time. For example,
the maximal safe dose, conditional on exposure time, can defined as min{φij1 , χij1 /t}, and
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(n)

(n)

posterior samples obtained from min{φij1 , χij1 /t}. Given these posterior draws, one can
proceed with the straightforward construction of standard posterior summaries, like means,
maxima a posteriori, modes, quantiles and credible regions. We may also be interested
in testing for a dose-time interaction. The expected inclusion probability of the dose-time
P (n)
(n)
interaction function can be estimated using posterior draws ρij as p̂ij = n ρij /N Given
the prior described in (5), this posterior probability is known to adjust for multiplicities
and can be used to test for a dose-time interaction. Scott and Berger (2006) for example,
recommend selecting the median model, that is including all interactions for which p̂ij > 0.5.
Also of interest is an estimate of the dose-response surface mij (d, t) for particle i and outcome
j. This surface is, of course, defined in an infinite-dimensional space. However, given the
basis-function representation introduced in Section 2.1, we only need finite draws from the
parameter set of interest. More precisely, draws from the marginal posterior distribution of
the dose-response surface for any dose d ∈ [0, D] and time t ∈ [0, T ] are given by

(n)
 α(n) + B(d, φ(n) )0 β (n) + B(t, ψ (n) )0 γ (n)
if ρij = 0
ij
ij
ij
ij
ij
(n)
mij (d, t) =
(n)
 α(n) + B(d, φ(n) )0 β (n) + B(t, ψ (n) )0 γ (n) + B(dt, χ(n) )0 δ (n)
if ρij = 1
ij
ij
ij
ij
ij
ij
ij
(18)
(n)

(n)

(n)

(n)

(n)

For each φij , ψij , βij , φij , and αij , k = 1, ..., M , we evaluate the dose-response
function given in (18) over a grid of values D̃ = (d1 , ..., dn )0 and T̃ = (t1 , ..., tn )0 . The posterior
(n)

mean of the samples mij , k = 1, ..., M , at each value of D̃ and T̃ can be used to summarize
the fit of the dose-response surface, as shown in Figures 3 and 4. Other quantities of interest
include the posterior distribution of the dose response function fij (d; φij , β ij ), duration
response function gij (t; ψ ij , γ ij ), and dose-time interaction function hij (dt; χij , δ ij ). Draws
from the marginal posterior distribution of these functions for any dose d ∈ [0, D] and time
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t ∈ [0, T ] are given by
(n)

(n)

(n)

fij (d; φij , β ij ) = B(d, φij )0 β ij
(n)

(n)

(n)

gij (t; ψ ij , γ ij ) = B(t, ψij )0 γ ij
(n)

(n)

(19)

(n)

hij (dt; χij , δ ij ) = B(dt, χij )0 δ ij

For each draw, we evaluate the dose response functions over a grid of values d ∈ D̃, and
the duration response functions over a grid of values t ∈ T̃ . As described before, standard
point-wise posterior summaries can be obtained in a straightforward fashion. Simultaneous
confidence bands for the functional effect of interest can be constructed following the Monte
Carlo approximation suggested by Baladandayuthapani et al. (2005).
More summaries of interest can be obtained in a numerical fashion. For example, the
posterior distribution for maximal response value, m∗ij = max{mij (d, t); d ∈ [0, D], t ∈
(n)

[0, T ]}, may be obtained evaluating mij (d, t) over a fine grid of doses D̃ and times T̃ .
∗(n)

An approximate posterior draw from m∗ij can be defined as mij

(n)

= max{mij (d, t); d ∈

D̃, t ∈ T̃ }. Given smoothness constraints on mij (d, t) defined in Section 2.1, the foregoing
procedure is likely to provide a good approximation to the posterior distribution of the
maximal response value, provided D̃ and T̃ define a sufficiently detailed evaluation grid.
Similar procedures may be adopted to obtain inference on other risk assessment parameters
like ECαs or BMDs.

4 APPLICATIONS
4.1 Synthetic Data
To assess estimation of the model presented in Section 2, we present a simulation study in
Supplementary Appendix B. The dose and time kinetics were simulated in an additive fashion
from various parametric functions including both canonical and non-canonical profiles that
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are still reasonably interpretable under a toxicity framework. We also placed increasingly
conservative priors on the population level parameters λφi and λφi , in order to assess the
sensitivity of the model results to our choice of prior parameters. In Supplementary Appendix
C, we provide an additional sensitivity analysis assessing our model results to our choice of
prior model for our change-point parameters. We compare our prior model results to both
a truncated normal prior and a parameterization of the bivariate beta prior which results in
a uniform prior on the simplex.
Our results indicate that our model is robust to model mis-specification and is not very
sensitive to our choice of prior. We do hover maintain that using the bivariate beta prior
defined in (8) is likely to be more appropriate in data analytic frameworks, as the implied
stochastic behavior of the response surface, a priori, reflects more closely usual biological
mechanisms of toxicity. More specifically, it assigns zero probability of toxicity to zero dose
and time, where toxicity is indeed not supposed to occur.

4.2 Case Study Background
We illustrate the proposed methodology analyzing data on macrophage cells (RAW cells)
exposed to eight different metal and metal oxide nanoparticles, monitored in relation to four
cytotoxicity parameters. All four outcomes are measured over a grid of ten doses and seven
times (hours) of exposure (see Figures 3 and 4). Cytotoxicity screening is based on the hierarchical oxidative stress model (George et al. 2010). More specifically, a multi-parametric
assay that utilizes four compatible dye combinations and subsequent change in fluorescence
read-out was used to measure four responses relating to the highest tier of oxidative stress
(toxic oxidative stress). The four responses measured include mitochondrial superoxide formation (MSF), loss of mitochondrial membrane potential (MMP), elevated intracellular calcium (EIC), and cellular membrane damage (CMD). Figure 1 provides fluorescence images
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of cells exposed to various nanomaterials (50 µg/mL and 3 hours), including quantum dot,
platinum, and a negative control consisting of no nanomaterials. (Row 1) includes images
of cells treated with a dye combination including the MitoSox dye, which permeates the
mitochondria and fluoresces red when oxidized by superoxide. Red fluorescence measured
in cells treated with MitoSox is therefore a measure of mitochondrial superoxide formation.
Similarly, in (Row 2) cells are treated with a dye combination including JC1, which stains
the cytoplasm red in healthy cells, but forms a monomer in cells with decreased membrane
potential and consequently stains the cytoplasm green. Finally, in (Row 3) cells are strained
with a dye combination including Fluo-4 and Propidium Iodide (PI). In cells with damaged
membranes Fluo-4 is able to permeate the cell and bind to DNA where is causes the nucleus
to emit a red florescence. Fluo-4 is a dye that emits a green fluorescence in the cytoplasm
in cells with elevated intracellular calcium. Each sample was also stained with a Hoechst
dye which causes all cell nuclei to emit a blue florescence, and allows for a count of the total
number of cells. An analysis of the fluorescence readout, measured at varying wavelengths,
results in a measure of the percentage of cells positive for each response. Figure 1 also provides a heat map of the raw responses for each particle and outcome, where colder colors
(blues and greens) indicate a smaller percentages of cells positive for the response and warmer
colors (oranges and reds) indicate a higher percentage of cells positive for the response. The
final data was normalized using a logit transformation to unconstrain the support so that it
can take on values between -∞ and ∞. Our inferences are based on 20,000 MCMC samples
from the posterior distribution in (14), after discarding a conservative 60,000 iterations for
burn-in. MCMC sampling was performed in R version 2.10.0, and convergence diagnostics
were performed using the package CODA (Convergence Diagnostics and Output Analysis),
(Plummerm et al. 2006).
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4.3 Case Study Analysis and Results
We fit the model described in Section 2.1 to the metal oxide data-set described in the previous Section. The prior on the interior knots parameters was modeled using the simplified
density described in (9). A set of relatively non-informative Gamma(2, 1) and Gamma(3, 1)
priors were considered for the components of both λφi and λψi and a vague B2 (2, 3, 1, 1, DT )
prior for our dose-time interaction change-point parameter χij . We also fixed βij2 = 0 and
γij2 = 0, assuming no effect before φij1 and ψij1 , thereby allowing us to interpret φij1 as the
maximal safe dose and ψij1 as the maximal safe exposure time, in the absence of a dose-time
interaction. Similarly, when ρij = 1, we fixed δij2 = 0. We placed Gamma(.01, .01) priors
on the 1/σj parameters, Gamma(1, .1) priors on all remaining precision parameters and
N (0, 10) priors on the αoi parameters. The βoi and γoi are modeled as truncated multivariate normals with mean 1 and a covariance matrix with diagonal elements 10 and off diagonal
elements 0. Finally, we placed a prior distribution on the degrees of freedom parameter ν,
for the T-distributed error described in Section 2.1. We specified the prior to be uniform
on 1,2,4,8,16, and 32 degrees of freedom (Besag and Higdon 1999). In concordance with our
synthetic data experiments, a sensitivity analysis on the case study data-set proved robust
to reasonable variations in the prior specification.
Figures 3 and 4 illustrate data and results associated with two of the particles examined
in this HTS study. Particularly, we report inference for platinum and quantum dot nanomaterials for each of the 4 cytotoxicity outcomes. Inference for the remaining 6 particles
is reported in supplementary Appendix D. In these two figures, column 1 shows expected
posterior dose-response surfaces across dose and time for all outcomes. As the posterior expectation marginalizes over the interior knots, smooth surfaces reflect the uncertainty about
the location of these change-points and provide an illustration of how the proposed technique
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will adjust for smoothness in an unsupervised fashion. Also included are functional posterior
expectations associated with dose response curves fij (d) (column 2), which represent the effect due to dose, duration response curves gij (t) (column 3), which represent the effect due
to exposure time, and the expected dose-time interaction function hij (t) (column 4).
Figure 5 provides a plot of the estimated median response, relative to the background, for
different doses and times of exposure. Blue colors indicate safety regions or areas of reduced
risk to the cells, while red colored regions indicate increased risk of cytotoxicity. Finally,
figure 6 provides posterior summary estimates including mean and 95% posterior intervals
for the maximal safe dose, conditional on the duration of exposure. Note that in the absence
of a dose-time interaction, the maximal safe dose is the same across all exposure times.
Quantum dot (QD) shows a relatively high toxic response for plasma membrane damage and mitochondrial superoxide formation. In particular, we see a more pronounced dose
effect for membrane damage and both a time, dose and significant dose-time interaction
(p=.99) effect for mitochondrial superoxide formation. This supports what has previously
been demonstrated in conventional assays that QD nanoparticles stabilized by toluene are
capable of inducing tier 2 and 3 oxidative stress responses induced by the toluene (George
et al. 2011). Platinum (Pt) shows a high dose and time response for mitochondrial superoxide formation, including a significant dose-time interaction effect (p=.99), and a pronounced
time effect for elevated calcium but not for mitochondrial depolarization or membrane damage, indicating that the particle induced sub-lethal effects to the cell without cytotoxicity.
The Zinc oxide nanoparticle (ZnO), reported in supplementary Appendix D, shows a relatively high toxic response for plasma membrane damage, elevated calcium and mitochondrial
depolarization. In particular, we see a more pronounced time effect for the elevated calcium
and both a time and dose response for membrane damage and mitochondrial depolarization.
This again verifies what has previously been demonstrated in conventional assays, since ZnO
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nanoparticles are capable of inducing tier 2 and 3 oxidative stress responses through Zn+
2
release (George et al. 2010). In contrast, the gold nanoparticle (Al), also reported in supplementary Appendix D, shows very little response for all outcomes, indicating that, compared
to the other particles, it has small risk of inducing a sublethal or lethal cytotoxic response.

5 DISCUSSION
In this article, we propose a statistical framework for modeling dependent dose-response
surfaces over multivariate outcomes. The proposed methodology accounts for dose and duration kinetics jointly using a flexible model which does not compromise interpretability.
We account for the multivariate nature of the data using the hierarchical framework and
thereby efficiently combine information and borrow strength across cellular injury patterns.
We account for the non-robust nature of the data by allowing for particle specific variance
inflation, resulting in a T-distributed model for the error structure.
The main challenge associated with this class of models is finding the right balance between model complexity and model interpretability. An alternative formulation of the doseresponse surface would seek inference for a general smooth surface mij (d, t). However, our
simplified approach, based on the assumptions of additivity and linearity, maintains a very
appealing level of interpretability, allowing for the definition of specific risk assessment parameters while maintaining an adequate level of flexibility. A related generalization of the
proposed additive framework would include a more general class of functional interactions
to account for a possible synergistic effect between dose and duration of exposure. This
would come at the cost of reduced interpretability, but, at the same time, could be of clear
scientific interest in some contexts. In this initial modeling effort, we choose to work with a
T distributed error structure and therefore normalize our response to unconstrain the sup23

port so that it can take on values between -∞ and ∞. An alternative formulation could
retain the original scale of the data, but rather define a generalized multivariate model such
that the outcome distribution can be described using binomial or beta random quantities.
This extension, would require a substantial increase in computational complexity, with the
possible need to consider numerical or analytical approximations, but it is clearly worthy of
further methodological exploration.
The hierarchical formulation introduced in this article is easily adapted to the case where
multiple cell lines are used to test for cytotoxicity. A natural integration strategy, would
perhaps find motivation in the meta analytic framework, with information shared between
experiments via the structuring of one extra level in the hierarchy.
Finally, the proposed model can also be expanded by the inclusion of covariates. This
is naturally defined as an extension to stage 3 of the model introduced in Section 2. The
addition of covariates is especially important for relating specific ENM properties to toxicity,
and is therefore an important area for future work.
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Figure 1: Fluorescence images and heat map of raw data. On the left are fluorescence
images of RAW cells treated with various nanomaterials (quantum dot, platinum, and a negative control) and dyed with compatible dye combinations including MitoSox, JC1, PI, and
Fluo-4. The subsequence fluorescence read-out, measured at varying wavelengths, provides
a measure of the number of cells positive for the response. On the left is a heat map of the
raw data for each particle and outcome. Colder colors indicate a smaller percentage of cells
positive for the response and warmer colors indicate a larger percentage of cells positive for
the response.

Parameter
∗
β3ij
∗
γ3ij
φ1ij
ψ1ij
m∗ij

Model function
Dose response slope between φij1 and φij2
Duration response slope between φij1 and φij2
Dose response change point 1
Duration response change point 1
Evaluated numerically

Parameter interpretation
Overall dose effect
Overall exposure time Effect
Maximal safe dose
Maximal safe exposure time
Maximal response

Table 1: Risk assessment parameters. ENM level risk assessment parameters associated
with the hierarchical model introduced in 2.1. For each parameter we summarize its function
in the model and the related interpretation as a cytotoxicity risk factor.

Figure 2: Dose response as a change point model. (left) B-spline basis function of
degree 1, corresponding to change points (interior knots) at log doses of 1.5 and 4.5. (Middle)
Example dose-response curve. The basis function on the left corresponds to a spline function
with 2 change points. Each random change point has a corresponding distribution which
results in a smooth dose response curve. (Right) Example of a marginal prior distribution
on the change points corresponding to the dose response curve on the left. This formulation
favors (a-priori) the choice of conservative values for the location of the first change-point
(solid line) and a relatively diffuse prior for our second change-point (dotted line)
.

Figure 3: Fitted response curves for the platinum nanomaterial (P t). Fitted response surfaces (column 1), dose-response function, fij (d) (column 2), duration-response
function, gij (t) (column 3), dose/duration interaction function, hij (dt) (column 4) and associated 95% posterior intervals

Figure 4: Fitted response curves for the quantum dot nanomaterial (QD). (left)
Fitted response surfaces (column 1), dose-response function, fij (d) (column 2), durationresponse function, gij (t) (column 3), dose/duration interaction function, hij (dt) (column 4)
and associated 95% posterior intervals

Figure 5: Safe exposure regions for the quantum dot (QD) and platinum (P t)
nanomaterials. For each particle and outcome we can define dose and time exposure
regions which do not induce cytotoxicity. Red colored regions indicate greater cytotoxicity
to the cells, whereas blue colored regions indicate reduced risk. Contour lines quantitate the
median estimated response, relative to the background, where zero response areas can be
interpreted as safe exposure regions.

Figure 6: Maximal Safe Dose for the quantum dot (QD) and platinum (P t) nanomaterials. Posterior summary estimates of the maximal safe dose, conditional on exposure
time, including the posterior mean and associated 95% posterior intervals. In the case of no
interaction, the maximal safe dose is the same across all times.

